JORGE E CORTES to Heart Diseases
This is a "connection" page, showing publications JORGE E CORTES has written about Heart Diseases.
Connection Strength
0.614
-
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820.
Score: 0.487
-
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607.
Score: 0.100
-
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9.
Score: 0.013
-
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009 Apr 01; 115(7):1381-94.
Score: 0.013